Cargando…

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

INTRODUCTION: We and others have previously shown that antibodies against cyclic citrullinated proteins (anti-CCP) precede the development of rheumatoid arthritis (RA) and in a more recent study we reported that individuals who subsequently developed RA had increased concentrations of several cytoki...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokkonen, Heidi, Mullazehi, Mohammed, Berglin, Ewa, Hallmans, Göran, Wadell, Göran, Rönnelid, Johan, Rantapää-Dahlqvist, Solbritt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241357/
https://www.ncbi.nlm.nih.gov/pubmed/21291540
http://dx.doi.org/10.1186/ar3237
_version_ 1782219516040708096
author Kokkonen, Heidi
Mullazehi, Mohammed
Berglin, Ewa
Hallmans, Göran
Wadell, Göran
Rönnelid, Johan
Rantapää-Dahlqvist, Solbritt
author_facet Kokkonen, Heidi
Mullazehi, Mohammed
Berglin, Ewa
Hallmans, Göran
Wadell, Göran
Rönnelid, Johan
Rantapää-Dahlqvist, Solbritt
author_sort Kokkonen, Heidi
collection PubMed
description INTRODUCTION: We and others have previously shown that antibodies against cyclic citrullinated proteins (anti-CCP) precede the development of rheumatoid arthritis (RA) and in a more recent study we reported that individuals who subsequently developed RA had increased concentrations of several cytokines and chemokines years before the onset of symptoms of joint disease. Here we aimed to evaluate the prevalence and predictive values of anti-CCP antibodies of IgG, IgM and IgA isotype in individuals who subsequently developed RA and also to relate these to cytokines and chemokines, smoking, genetic factors and radiographic score. METHODS: A case-control study (1:4 ratio) was nested within the Medical Biobank and the Maternity cohorts of Northern Sweden. Patients with RA were identified from blood donors predating the onset of disease by years. Matched controls were selected randomly from the same registers. IgG, IgA and IgM anti-CCP2 antibodies were determined using EliA anti-CCP assay on ImmunoCAP 250 (Phadia AB, Uppsala, Sweden). RESULTS: Of 86 patients with RA identified as blood donors prior to the onset of symptoms, samples were available from 71 for analyses. The median (Q1 to Q3) predating time was 2.5 years (1.1 to 5.9 years). The sensitivity of anti-CCP antibodies in the pre-patient samples was 35.2% for IgG, 23.9% for IgA, and 11.8% for IgM. The presence of IgG and IgA anti-CCP antibodies was highly significant compared with controls. IgG and IgA anti-CCP2 predicted RA significantly in conditional logistic regression models odds ratio (OR) = 94.1, 95% confidence interval (CI) 12.7 to 695.4 and OR = 11.1, 95% CI 4.4 to 28.1, respectively, the IgM anti-CCP showed borderline significance OR = 2.5 95% CI 0.9 to 6.3. Concentrations of all anti-CCP isotypes increased the closer to the onset of symptoms the samples were collected with an earlier and higher increase for IgG and IgA compared with IgM anti-CCP. IgA and IgG anti-CCP positive individuals had different patterns of up-regulated chemokines and also, smoking brought forward the appearance of IgA anti-CCP antibodies in pre-RA individuals. CONCLUSIONS: Anti-CCP2 antibodies of both the IgG and IgA isotypes pre-dated the onset of RA by years; also, both IgG and IgA anti-CCP2 antibodies predicted the development of RA, with the highest predictive value for IgG anti-CCP2 antibodies.
format Online
Article
Text
id pubmed-3241357
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32413572011-12-17 Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis Kokkonen, Heidi Mullazehi, Mohammed Berglin, Ewa Hallmans, Göran Wadell, Göran Rönnelid, Johan Rantapää-Dahlqvist, Solbritt Arthritis Res Ther Research Article INTRODUCTION: We and others have previously shown that antibodies against cyclic citrullinated proteins (anti-CCP) precede the development of rheumatoid arthritis (RA) and in a more recent study we reported that individuals who subsequently developed RA had increased concentrations of several cytokines and chemokines years before the onset of symptoms of joint disease. Here we aimed to evaluate the prevalence and predictive values of anti-CCP antibodies of IgG, IgM and IgA isotype in individuals who subsequently developed RA and also to relate these to cytokines and chemokines, smoking, genetic factors and radiographic score. METHODS: A case-control study (1:4 ratio) was nested within the Medical Biobank and the Maternity cohorts of Northern Sweden. Patients with RA were identified from blood donors predating the onset of disease by years. Matched controls were selected randomly from the same registers. IgG, IgA and IgM anti-CCP2 antibodies were determined using EliA anti-CCP assay on ImmunoCAP 250 (Phadia AB, Uppsala, Sweden). RESULTS: Of 86 patients with RA identified as blood donors prior to the onset of symptoms, samples were available from 71 for analyses. The median (Q1 to Q3) predating time was 2.5 years (1.1 to 5.9 years). The sensitivity of anti-CCP antibodies in the pre-patient samples was 35.2% for IgG, 23.9% for IgA, and 11.8% for IgM. The presence of IgG and IgA anti-CCP antibodies was highly significant compared with controls. IgG and IgA anti-CCP2 predicted RA significantly in conditional logistic regression models odds ratio (OR) = 94.1, 95% confidence interval (CI) 12.7 to 695.4 and OR = 11.1, 95% CI 4.4 to 28.1, respectively, the IgM anti-CCP showed borderline significance OR = 2.5 95% CI 0.9 to 6.3. Concentrations of all anti-CCP isotypes increased the closer to the onset of symptoms the samples were collected with an earlier and higher increase for IgG and IgA compared with IgM anti-CCP. IgA and IgG anti-CCP positive individuals had different patterns of up-regulated chemokines and also, smoking brought forward the appearance of IgA anti-CCP antibodies in pre-RA individuals. CONCLUSIONS: Anti-CCP2 antibodies of both the IgG and IgA isotypes pre-dated the onset of RA by years; also, both IgG and IgA anti-CCP2 antibodies predicted the development of RA, with the highest predictive value for IgG anti-CCP2 antibodies. BioMed Central 2011 2011-02-03 /pmc/articles/PMC3241357/ /pubmed/21291540 http://dx.doi.org/10.1186/ar3237 Text en Copyright ©2011 Kokkonen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kokkonen, Heidi
Mullazehi, Mohammed
Berglin, Ewa
Hallmans, Göran
Wadell, Göran
Rönnelid, Johan
Rantapää-Dahlqvist, Solbritt
Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
title Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
title_full Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
title_fullStr Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
title_full_unstemmed Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
title_short Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
title_sort antibodies of igg, iga and igm isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241357/
https://www.ncbi.nlm.nih.gov/pubmed/21291540
http://dx.doi.org/10.1186/ar3237
work_keys_str_mv AT kokkonenheidi antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis
AT mullazehimohammed antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis
AT berglinewa antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis
AT hallmansgoran antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis
AT wadellgoran antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis
AT ronnelidjohan antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis
AT rantapaadahlqvistsolbritt antibodiesofiggigaandigmisotypesagainstcycliccitrullinatedpeptideprecedethedevelopmentofrheumatoidarthritis